Entera Bio Ltd

ENTX

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    20

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,941.1234.54-0.38%
HKSE24,139.57111.200.46%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers